Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + mFOLFOX6 in Resectable Colorectal Liver Metastases
NCT05948072Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jul 2023
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of KL-140 in colorectal cancer (CRC) (2 arms), sponsored by Fudan University. Primary endpoint: Event-free survival at 3 years. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
KL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05948072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948072.